Pembrolizumab in recurrent or metastatic medullary thyroid cancer
This study did not support the hypothesis that sequencing immunotherapy with an immune checkpoint inhibitor could enhance the clinical activity of the immune checkpoint, which has not demonstrated independent activity in that disease previously.
Authors
- Melissa L. Abel (ORCID: https://orcid.org/0000-0001-8941-0206)
- Jaydira Del Rivero (ORCID: https://orcid.org/0000-0001-9710-4030)
- Jennifer L. Marté
- Lisa M. Cordes (ORCID: https://orcid.org/0000-0003-3833-4084)
- Ravi Amrit Madan (ORCID: https://orcid.org/0000-0001-5106-8636)
- Renee N. Donahue (ORCID: https://orcid.org/0000-0002-6828-3073)
- Fatima Karzai (ORCID: https://orcid.org/0000-0002-3244-1332)
- J. L. Gulley
- J Schlom
- Ann Gramza
Institutions
- National Institutes of Health (US)
- Georgetown University Medical Center (US)
- MedStar Georgetown University Hospital (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1093/oncolo/oyaf348
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00